Trial · NCT06965244
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients who achieve decrease of at least 50% from baseline in the CLASI activity (CLASI-A) score | At week 16 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Percentage of patients reaching CLASI-A 70 | At week 16 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Proportion of participants who achieve complete or almost complete response (CLASI-A 0-3) | At week 16 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Percentage of patients reaching CLASI-A 70 | At week 24 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Proportion of participants who achieve complete or almost complete response (CLASI-A 0-3) | At week 24 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Variation of Quality of life using DLQI | At week 16 | DLQI : Dermatology Life Quality Index |
| Secondary | Variation of Quality of life using DLQI | At week 24 | DLQI : Dermatology Life Quality Index |
| Secondary | SLE activity using SLEDAI | Up to 24 weeks | SLEDAI : Systemic Lupus Erythematosus Disease Activity Index |
| Secondary | SLE flare using SENELA-SLEDAI Flare Index (SFI) | Up to 24 weeks | SELENA : Safety of Estrogens in Lupus Erythematosus National Assessment SLEDAI : Systemic Lupus Erythematosus Disease Activity Index |
| Secondary | Variation of GCs dose | Between inclusion and week 24. | |
| Secondary | Variation of damage in each group using CLASI-D | At week 24 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Variation of damage in each group using CLASI-D | At week 16 | CLASI : Cutaneous LE disease Area and Severity Index |
| Secondary | Rate of adverse events | Up to 24 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06965244/registered